Endometrial Cancer Trial, Recruiting NCT07453459 Sponsor: Washington University School of Medicine Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT07453459
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 25 and 65 years old
  • People who still have their cervix (it has not been removed)
  • People who report that they have not had a cervical cancer screening in the last 3 years
  • People who own a smartphone
  • People who have internet access to use the Teal Health mobile app and join a Zoom video call
  • People who can read, speak, write, and understand English well enough to complete a survey and an interview

Who may not be able to join:

  • People who are currently experiencing abnormal vaginal bleeding or discharge
  • People who have a history of cancer of the reproductive system
  • People who have a weakened or compromised immune system
  • People who were exposed to a medication called Diethylstilbestrol (DES) before birth (confirm with trial site)
  • People who are currently pregnant or who have given birth within the last 6 weeks
  • People who have had treatment for a cervical precancer — such as a procedure called LEEP (loop electrosurgical excision procedure) or conization — within the last 25 years

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Michelle Silver, PhD, ScM, Washington University School of Medicine

Phone: 314-454-7903

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
17 April 2026
Est. completion
15 November 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Proportion of participants who returned HPV samples; Proportion of participants with completed referral visits; Time to sample return; Time to referral; Thematic findings addressing opportunity; Thematic findings addressing capability; Thematic findings addressing motivation; Thematic findings addressing behavior

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov